These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37932920)

  • 1. Fanconi Syndrome in Patients With Human Immunodeficiency Virus Treated With Tenofovir-Based Antiretroviral Therapy: A Systematic Literature Review.
    Joshi M; Clark B; Lee TA
    Ann Pharmacother; 2024 Aug; 58(8):857-869. PubMed ID: 37932920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of renal Fanconi syndrome in patients taking antiretroviral therapy including tenofovir disoproxil fumarate.
    Medland NA; Chow EP; Walker RG; Chen M; Read TR; Fairley CK
    Int J STD AIDS; 2018 Mar; 29(3):227-236. PubMed ID: 28764611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fanconi syndrome accompanied by renal function decline with tenofovir disoproxil fumarate: a prospective, case-control study of predictors and resolution in HIV-infected patients.
    Gupta SK; Anderson AM; Ebrahimi R; Fralich T; Graham H; Scharen-Guivel V; Flaherty JF; Fortin C; Kalayjian RC; Rachlis A; Wyatt CM
    PLoS One; 2014; 9(3):e92717. PubMed ID: 24651857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short Communication: Resolution of Tenofovir Disoproxil Fumarate Induced Fanconi Syndrome with Switch to Tenofovir Alafenamide Fumarate in a HIV-1 and Hepatitis B Coinfected Patient.
    Karris MY
    AIDS Res Hum Retroviruses; 2017 Jul; 33(7):718-722. PubMed ID: 28403627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials.
    Tao X; Lu Y; Zhou Y; Zhang L; Chen Y
    Int J Infect Dis; 2020 Apr; 93():108-117. PubMed ID: 31988012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system.
    Gupta SK
    AIDS Patient Care STDS; 2008 Feb; 22(2):99-103. PubMed ID: 18260800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal proximal tubulopathy in an HIV-infected patient treated with tenofovir alafenamide and gentamicin: a case report.
    Heron JE; Bloch M; Vanguru V; Saunders J; Gracey DM
    BMC Nephrol; 2020 Aug; 21(1):339. PubMed ID: 32787843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pharmacogenetic candidate gene study of tenofovir-associated Fanconi syndrome.
    Dahlin A; Wittwer M; de la Cruz M; Woo JM; Bam R; Scharen-Guivel V; Flaherty J; Ray AS; Cihlar T; Gupta SK; Giacomini KM
    Pharmacogenet Genomics; 2015 Feb; 25(2):82-92. PubMed ID: 25485598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment-limiting renal tubulopathy in patients treated with tenofovir disoproxil fumarate.
    Hamzah L; Jose S; Booth JW; Hegazi A; Rayment M; Bailey A; Williams DI; Hendry BM; Hay P; Jones R; Levy JB; Chadwick DR; Johnson M; Sabin CA; Post FA
    J Infect; 2017 May; 74(5):492-500. PubMed ID: 28130143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tenofovir alafenamide nephrotoxicity: a case report and literature review.
    Ueaphongsukkit T; Gatechompol S; Avihingsanon A; Surintrspanont J; Iampenkhae K; Avihingsanon Y; Udomkarnjananun S
    AIDS Res Ther; 2021 Aug; 18(1):53. PubMed ID: 34419091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.
    Gupta SK; Post FA; Arribas JR; Eron JJ; Wohl DA; Clarke AE; Sax PE; Stellbrink HJ; Esser S; Pozniak AL; Podzamczer D; Waters L; Orkin C; Rockstroh JK; Mudrikova T; Negredo E; Elion RA; Guo S; Zhong L; Carter C; Martin H; Brainard D; SenGupta D; Das M
    AIDS; 2019 Jul; 33(9):1455-1465. PubMed ID: 30932951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment.
    DeJesus E; Haas B; Segal-Maurer S; Ramgopal MN; Mills A; Margot N; Liu YP; Makadzange T; McCallister S
    AIDS Res Hum Retroviruses; 2018 Apr; 34(4):337-342. PubMed ID: 29368537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
    Mayer KH; Molina JM; Thompson MA; Anderson PL; Mounzer KC; De Wet JJ; DeJesus E; Jessen H; Grant RM; Ruane PJ; Wong P; Ebrahimi R; Zhong L; Mathias A; Callebaut C; Collins SE; Das M; McCallister S; Brainard DM; Brinson C; Clarke A; Coll P; Post FA; Hare CB
    Lancet; 2020 Jul; 396(10246):239-254. PubMed ID: 32711800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Life-threatening rhabdomyolysis and Fanconi syndrome related to tenofovir disoproxil fumarate administration in an HIV-infected patient.
    Favarel-Garrigues M; Hentzien M; Berger JL; Brunet A; Bani-Sadr F
    Med Mal Infect; 2020 Feb; 50(1):93-94. PubMed ID: 31506209
    [No Abstract]   [Full Text] [Related]  

  • 15. Tenofovir Alafenamide.
    Gibson AK; Shah BM; Nambiar PH; Schafer JJ
    Ann Pharmacother; 2016 Nov; 50(11):942-952. PubMed ID: 27465879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal function change after switching tenofovir disoproxil fumarate for tenofovir alafenamide in the HIV-positive patients of a metropolitan sexual health service.
    Turner D; Drak D; O'Connor CC; Templeton DJ; Gracey DM
    AIDS Res Ther; 2019 Dec; 16(1):40. PubMed ID: 31810490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of tenofovir alafenamide in people with HIV who experienced proximal renal tubulopathy on tenofovir disoproxil.
    Campbell L; Barbini B; Cromarty B; Hamzah L; Williams D; Winston A; Post FA;
    AIDS; 2024 Jul; 38(9):1442-1445. PubMed ID: 38932750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal safety of tenofovir alafenamide-based antiretroviral therapy in people with HIV: A mini-review.
    Zhao F; Lu H
    Biosci Trends; 2024 Jun; 18(2):141-152. PubMed ID: 38658364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypophosphatemic osteomalacia induced by tenofovir in HIV-infected patients.
    Mateo L; Holgado S; Mariñoso ML; Pérez-Andrés R; Bonjoch A; Romeu J; Olivé A
    Clin Rheumatol; 2016 May; 35(5):1271-9. PubMed ID: 24794489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Epi-TAF for Tenofovir Disoproxil Fumarate?
    Walensky RP; Horn TH; Paltiel AD
    Clin Infect Dis; 2016 Apr; 62(7):915-8. PubMed ID: 26658300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.